MedTrace Logo

Advanced Diffusion Imaging in Renal Cancer Patients

NCT06116253 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-05-08

No results posted yet for this study

Summary

The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

Conditions

  • Renal Cancer

Interventions

DEVICE

Magnetic Resonance Imaging (MRI) Scan

Participants will undergo a 1-hour research MRI scan.

DRUG

Tc-99m Pentetate

Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).

Sponsors & Collaborators

Principal Investigators

  • Eric Sigmund, PhD · NYU Langone Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2028-12-01
Completion
2028-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06116253 on ClinicalTrials.gov